Tarsus Pharmaceuticals
TARS
44 hedge funds and large institutions have $378M invested in Tarsus Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
7% more funds holding
Funds holding: 41 → 44 (+3)
0.85% more ownership
Funds ownership: 62.8% → 63.65% (+0.85%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less capital invested
Capital invested by funds: $410M → $378M (-$31.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$16.1M |
| 2 |
JG
Jefferies Group
New York
|
+$13.8M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$7.33M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$5.31M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$15.6M |
| 2 |
RI
RTW Investments
New York
|
-$14.1M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.05M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.25M |
| 5 |
Millennium Management
New York
|
-$2.73M |
TARS Hedge Fund Activity: Q2 2021 in Review
44 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q2 2021, worth a combined $378M — down 7.8% from $410M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TARS positions and 7 closed out — a net gain of 3 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $16.1M. The largest seller was Frazier Management, cutting an estimated $15.6M.
- 44 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q2 2021, up from 41 in Q1 2021.
- Funds reported $378M of Tarsus Pharmaceuticals stock for Q2 2021, down 7.8% quarter-over-quarter.
- 10 funds opened new Tarsus Pharmaceuticals positions in Q2 2021 and 7 closed out, a net change of +3 holders.
- The largest Tarsus Pharmaceuticals buyer in Q2 2021 was Cowen and Company, an estimated $16.1M added.
- The largest Tarsus Pharmaceuticals seller in Q2 2021 was Frazier Management, an estimated $15.6M sold.
Based on aggregated 13F filings for Q2 2021.